EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas
详细信息 查看全文
- 作者：Wen-Chiuan Tsai (2)
Ying Chen (3)
Li-Chun Huang (5)
Herng-Sheng Lee (2)
Hsin-I Ma (1)
Shih-Ming Huang (5)
Huey-Kang Sytwu (4)
Dueng-Yuan Hueng (1) (5) - 关键词：Astrocytoma ; Meningioma ; EMMPRIN ; GEO profile ; WHO grades ; Tumor stem ; like cells
- 刊名：Journal of Neuro-Oncology
- 出版年：2013
- 出版时间：September 2013
- 年：2013
- 卷：114
- 期：3
- 页码：281-290
- 全文大小：860KB
- 参考文献：1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncology 4:278-99
2. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY (2010) Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol 100:217-23. doi:10.1007/s11060-010-0164-2 CrossRef
3. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK (2007) MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 27:407-12 CrossRef
4. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res 41:D991–D995. doi:10.1093/nar/gks1193 CrossRef
5. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Muertter RN, Edgar R (2009) NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 37:D885–D890. doi:10.1093/nar/gkn764 CrossRef
6. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, Watsky MA, De Wever B, Calvo F, Mauviel A, Menashi S (2005) Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol 166:209-19. doi:10.1016/S0002-9440(10)62245-6 CrossRef
7. Sivak JM, Fini ME (2002) MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 21:1-4 CrossRef
8. Kahari VM, Saarialho-Kere U (1997) Matrix metalloproteinases in skin. Exp Dermatol 6:199-13 CrossRef
9. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-39. doi:10.1161/01.RES.0000070112.80711.3D CrossRef
10. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55:434-39
11. Kataoka H, DeCastro R, Zucker S, Biswas C (1993) Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 53:3154-158
12. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-36 CrossRef
13. Bordador LC, Li X, Toole B, Chen B, Regezi J, Zardi L, Hu Y, Ramos DM (2000) Expression of emmprin by oral squamous cell carcinoma. International journal of cancer Journal international du cancer 85:347-52 CrossRef
14. Rosenthal EL, Shreenivas S, Peters GE, Grizzle WE, Desmond R, Gladson CL (2003) Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 113:1406-410. doi:10.1097/00005537-200308000-00027 CrossRef
15. Gu ZD, Chen KN, Li M, Gu J, Li JY (2005) Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol 11:871-74
16. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Janicke F, Sauter G, Pantel K (2004) Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10:3422-428. doi:10.1158/1078-0432.CCR-03-0610 CrossRef
17. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R (2003) EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 20:161-69 CrossRef
18. Sier CF, Zuidwijk K, Zijlmans HJ, Hanemaaijer R, Mulder-Stapel AA, Prins FA, Dreef EJ, Kenter GG, Fleuren GJ, Gorter A (2006) EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer 118:2991-998. doi:10.1002/ijc.21778 CrossRef
19. Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS (2006) Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 49:388-95. doi:10.1111/j.1365-2559.2006.02516.x CrossRef
20. Tsai WC, Sheu LF, Nieh S, Yu CP, Sun GH, Lin YF, Chen A, Jin JS (2007) Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol 25:73-0. doi:10.1007/s00345-006-0110-2 CrossRef
21. van der Jagt MF, Sweep FC, Waas ET, Hendriks T, Ruers TJ, Merry AH, Wobbes T, Span PN (2006) Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 237:289-97. doi:10.1016/j.canlet.2005.06.009 CrossRef
22. Nabeshima K, Suzumiya J, Nagano M, Ohshima K, Toole BP, Tamura K, Iwasaki H, Kikuchi M (2004) Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas. J Pathol 202:341-51. doi:10.1002/path.1518 CrossRef
23. Gu J, Zhang C, Chen R, Pan J, Wang Y, Ming M, Gui W, Wang D (2009) Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr 168:705-10. doi:10.1007/s00431-008-0828-5 CrossRef
24. Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, Koono M, Wakisaka S (2000) Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 88:21-7 CrossRef
25. Hueng DY, Lin GJ, Huang SH, Liu LW, Ju DT, Chen YW, Sytwu HK, Chang C, Huang SM, Yeh YS, Lee HM, Ma HI (2011) Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. J Neurooncol 104:21-1. doi:10.1007/s11060-010-0467-3 CrossRef
26. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-73. doi:10.1016/j.ccr.2006.02.019 CrossRef
27. Schulte A, Gunther HS, Phillips HS, Kemming D, Martens T, Kharbanda S, Soriano RH, Modrusan Z, Zapf S, Westphal M, Lamszus K (2011) A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia 59:590-02. doi:10.1002/glia.21127 CrossRef
28. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-09. doi:10.1007/s00401-007-0243-4 CrossRef
29. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-63 CrossRef
30. Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Lee YC, Cheng YY, Liu LW, Wei HW, Lee HM (2010) Nodal promotes growth and invasion in human gliomas. Oncogene 29:3110-123. doi:10.1038/onc.2010.55 CrossRef
31. Ma HI, Chiou SH, Hueng DY, Tai LK, Huang PI, Kao CL, Chen YW, Sytwu HK (2011) Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation. J Neurosurg 114:651-62. doi:10.3171/2009.11.JNS091396 CrossRef
32. Jan HJ, Lee CC, Shih YL, Hueng DY, Ma HI, Lai JH, Wei HW, Lee HM (2010) Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro-oncology 12:58-0. doi:10.1093/neuonc/nop013 CrossRef
33. Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458-60. doi:10.1038/345458a0 CrossRef
34. Reichenbach P, Hoss M, Azzalin CM, Nabholz M, Bucher P, Lingner J (2003) A human homolog of yeast Est1 associates with telomerase and uncaps chromosome ends when overexpressed. Curr Biol 13:568-74 CrossRef
35. Kim SK, Wang KC, Cho BK, Lim SY, Kim YY, Oh CW, Chung YN, Kim CY, Lee CT, Kim HJ (2003) Adenoviral p16/CDKN2 gene transfer to malignant glioma: role of p16 in growth, invasion, and senescence. Oncol Rep 10:1121-126
36. Li H, Chen J, He M, Hui XH, Cai BW, Li Y (2007) Expression of CD147 and MMP-2 in human gliomas and its correlations with prognosis. Sichuan da xue xue bao Yi xue ban 38:396-99
37. Ho DM, Hsu CY, Ting LT, Chiang H (2002) Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94:1538-547 CrossRef
38. Rath P, Miller DC, Litofsky NS, Anthony DC, Feng Q, Franklin C, Pei L, Free A, Liu J, Ren M, Kirk MD, Shi H (2011) Isolation and characterization of a population of stem-like progenitor cells from an atypical meningioma. Exp Mol Pathol 90:179-88. doi:10.1016/j.yexmp.2010.12.003 CrossRef
39. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, Martinelli C, Lusis EA, Hegedus B, Gutmann DH, Giovannini M (2011) Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 30:2333-344. doi:10.1038/onc.2010.609 CrossRef
40. Hueng DY, Sytwu HK, Huang SM, Chang C, Ma HI (2011) Isolation and characterization of tumor stem-like cells from human meningiomas. J Neurooncol 104:45-3. doi:10.1007/s11060-010-0469-1 CrossRef
41. Chiu SH, Wang ID, Sytwu HK, Hueng DY (2013) Atypical meningioma. J Neurosurg 118:912-13. doi:10.3171/2012.11.JNS121838 CrossRef - 作者单位：Wen-Chiuan Tsai (2)
Ying Chen (3)
Li-Chun Huang (5)
Herng-Sheng Lee (2)
Hsin-I Ma (1)
Shih-Ming Huang (5)
Huey-Kang Sytwu (4)
Dueng-Yuan Hueng (1) (5)
2. Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
3. Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan, ROC
5. Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, ROC
1. Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, 325, Sec. 2, Cheng-Kung Road, Neihu, Taipei, 114, Taiwan, ROC
4. Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, ROC
文摘
High-grade primary brain tumors possessed poor outcome due to invasiveness. Extracellular matrix metalloproteinase inducer (EMMPRIN) stimulates peri-tumoral fibroblasts to secrete matrix metalloproteinase and promote invasiveness. This study hypothesized that high-grade brain tumors overexpress EMMPRIN. Analyzing the public delinked database from the Gene Expression Omnibus profile, the results showed that the EMMPRIN mRNA level was higher in WHO grade IV (n?=?81) than in grade III (n?=?19, p?<?0.0005) astrocytomas and non-tumor brain tissue controls (n?=?23, p?<?0.00001). The results of tissue microarray-based immunohistochemical (IHC) staining revealed that EMMPRIN levels positively correlated with WHO grades for astrocytomas (p?=?0.008) and meningiomas (p?=?0.048). EMMPRIN mRNA levels in conventional glioma cell lines (n?=?36) was not less than those in glioma primary culture cells (n?=?27) and glioblastoma stem-like cells (n?=?12). The GBM8401, U87MG, and LN229 human glioma cell lines also overexpressed EMMPRIN. Hematoxylin and eosin, IHC, and immunofluorescence staining of xenografts confirmed that high-grade brain tumors overexpressed EMMPRIN. Lastly, Kaplan–Meier analysis revealed poorer survival in WHO grade IV (n?=?56) than in grade III astrocytomas (n?=?21, by log-rank test; p?=?0.0001, 95?% CI: 1.842-.053). However, in high-grade astrocytomas, there was no difference in survival between high and low EMMPRIN mRNA levels. Thus, this study identified that high-grade brain tumors overexpress EMMPRIN, which positively correlates with WHO grades in human astrocytomas and meningiomas, and suggests that EMMPRIN may be a therapeutic target of brain tumor.